Involving Virus Or Bacteriophage Patents (Class 435/5)
  • Patent number: 10238747
    Abstract: A vaccine for immunization against Type A influenza virus is provided having an immunologically effective amount of peptide constructs obtained by linking together two or more peptides based on or derived from different molecules, and methods for producing the same. The peptide constructs have the formula P1-x-P2 or P2-x-P1 where P1 is associated with Type A influenza highly conserved protein such as but not limited to M2e matrix protein, NP1 nucleoprotein, HA2 core 1, and HA2 core 2, where P2 is a peptide construct causing a Th1 directed immune response by a set or subset of T cells to which the peptide P1 is attached or that binds to a dendritic cell or T cell receptor causing said set or subset of dendritic cell or T cells to which the peptide P1 is attached to initiate and complete, an immune response, and x is a direct bond or divalent linker for covalently bonding P1 and P2.
    Type: Grant
    Filed: December 13, 2011
    Date of Patent: March 26, 2019
    Assignee: Cel-Sci, Corp
    Inventor: Daniel H. Zimmerman
  • Patent number: 10235622
    Abstract: A computing device identifies a pattern in a dataset. A first neural network model is executed using data points as input to input nodes of the first neural network model to generate first output node data. A second neural network model is executed using the first output node data as input to input nodes of the second neural network model to generate second output node data. The second output node data includes a plurality of output values for each x-value of the plurality of data points. For each x-value, an output value of the plurality of output values is associated with a single pattern type of a plurality of predefined pattern types. For each pattern type of the plurality of predefined pattern types, a start time and a stop time is identified when the output value for the associated pattern type exceeds a predefined pattern window threshold value.
    Type: Grant
    Filed: July 25, 2017
    Date of Patent: March 19, 2019
    Assignee: SAS INSTITUTE INC.
    Inventors: Stuart Andrew Hunt, Samuel Paul Leeman-Munk, Richard Welland Crowell
  • Patent number: 10234456
    Abstract: The present invention provides an easy-to-use and higher-sensitivity immunochromatography device for an RSV, the device using an antibody that binds specifically to F protein of the RSV in a determination region of a chromatography medium, a test kit by an immunochromatography method, and a method for detecting an RSV using these device and kit. The present invention relates to an immunochromatography device in which not only an antibody that binds specifically to F protein of an RSV but also an antibody that binds specifically to N protein of the RSV is solid-phased in a determination region of a chromatography medium. The present invention also relates to a test kit by an immunochromatography method, and a method for detecting an RSV using these device and kit.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: March 19, 2019
    Assignees: TANAKA KIKINZOKU KOGYO K.K., ALFERESA PHARMA CORPORATION
    Inventors: Mieko Kosaka, Hiromi Taguchi, Noboru Sakai, Daisuke Itoh, Hisahiko Iwamoto
  • Patent number: 10231998
    Abstract: A method of radiation-free hematopoietic stem cell (HSC) transplantation comprises administering to a mammalian subject one or two doses of 2 to 10 mg/kg body weight of a purine base analog, such as 6TG as a pre-conditioning step. The method further comprises engrafting into the subject hypoxanthine-guanine phosphoribosyltransferase (HPRT)-deficient donor HSCs within 48 to 72 hours of the pre-conditioning step; and administering to the subject about 1 to 5 mg/kg of the purine base analog every two to four days for two to eight weeks following the engrafting step. The method is performed in the absence of pre-conditioning via radiation. The subject is therefore not treated with myeloablative radiation in preparation for transplantation, and thus the subject is free of myeloablative radiation-induced toxicity.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: March 19, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Noriyuki Kasahara, Robert H. Schiestl, Katrin Hacke, Akos Szakmary, Gay M. Crooks
  • Patent number: 10227637
    Abstract: Provided are a PNA probe for detecting nucleotide polymorphism of a target gene, a melting curve analysis method for detecting the nucleotide polymorphism of the target gene using the same, a nucleotide polymorphism analysis method of a target gene including the melting curve analysis method, and a kit for detecting the nucleotide polymorphism of the target gene containing the PNA probe. It is characterized that the PNA probe according to the present invention contains negative charge molecules. The modified PNA probe according to the present invention contains the negative charge molecules to have a high recognition ability with respect to a target DNA and a high coupling ability to the target DNA and to be rapidly dissociated by heat, such that the nucleotide polymorphism analysis may be relatively easily performed even in a heterozygous sample showing two melting curve graphs, and two or more adjacent single nucleotide polymorphisms may be simultaneously analyzed.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: March 12, 2019
    Assignee: PANAGENE INC.
    Inventors: Goon Ho Joe, Sung-Kee Kim, Heekyung Park, Chwang Siek Park, Se Ryun Kim, Yongtae Kim, Su Nam Kim
  • Patent number: 10220383
    Abstract: A sampling and assay kit comprises a cuvette for holding a quantity of a buffer solution and a sample holder including a capillary tube for obtaining a sample. The sample holder includes a body portion which holds the capillary tube. The body portion when inserted in the cuvette, is effective to position the capillary tube within the cuvette at a predetermined position above the end of the cuvette.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: March 5, 2019
    Assignee: Orion Diagnostica OY
    Inventors: Jukka Laukkonen, Jaana Raussi, Sanna Eilola, Jaakko Rissanen
  • Patent number: 10214750
    Abstract: Systems and methods are disclosed herein for use in transducing, activating, and otherwise treating cells. Cells are introduced into an inner layer of a multi-layered stack that defines at least one flow chamber and a plurality of cell entrainment regions. Vertical flow through the stack entrains the cells in the cell entrainment regions along with genetic information introduction agents or other additives, before the cells are washed using a reverse vertical flow and are collected from the device.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: February 26, 2019
    Assignee: The Charles Stark Draper Laboratory, Inc.
    Inventors: Jeffrey T. Borenstein, Joseph L. Charest, Christopher M. DiBiasio, Dorit Berlin, Jenna Balestrini, Jose A. Santos, Vishal Tandon
  • Patent number: 10215763
    Abstract: The present embodiments disclose methods for estimating PrPSc concentration in fluids and tissues by quantitative PMCA.
    Type: Grant
    Filed: May 18, 2011
    Date of Patent: February 26, 2019
    Assignee: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Claudio Soto, Baian Chen, Rodrigo Morales
  • Patent number: 10207268
    Abstract: A sample plate comprising a sample well is disclosed. The sample well can comprise one or more bead retaining chambers. A method of using the sample plate and a kit comprising the sample plate is also disclosed.
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: February 19, 2019
    Assignee: Dynex Technologies, Inc.
    Inventors: Adrian Bunce, Andrew Fusellier
  • Patent number: 10206632
    Abstract: A method for cardiovascular-dynamics correlated imaging includes receiving a time series of images of at least a portion of a patient, receiving a time series of cardiovascular data for the patient, evaluating correlation between the time series of images and the time series of cardiovascular data, and determining a property of the at least a portion of a patient, based upon the correlation. A system for cardiovascular-dynamics correlated imaging includes a processing device having: a processor, a memory communicatively coupled therewith, and a correlation module including machine-readable instructions stored in the memory that, when executed by the processor, perform the function of correlating a time series of images of at least a portion of a patient with a time series of cardiovascular data of the patient to determine a property of the at least a portion of a patient.
    Type: Grant
    Filed: July 27, 2015
    Date of Patent: February 19, 2019
    Assignee: THE TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Ryan J. Halter, Keith D. Paulsen, Alexander Hartov
  • Patent number: 10206995
    Abstract: The invention relates to vaccine compositions including CEV serogroup immunogens, attenuated and inactivated viruses of the CEV serogroup and chimeric Bunyaviridae. Also disclosed are methods of treating or preventing CEV serogroup infection in a mammalian host, methods of producing a subunit vaccine composition or an immunogenic composition, isolated polynucleotides comprising a nucleotide sequence encoding a CEV serogroup immunogen, methods for detecting La Crosse virus (LACV) infection in a biological sample and infectious chimeric Bunyaviridae.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: February 19, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Stephen S. Whitehead, Richard S. Bennett, Brian R. Murphy
  • Patent number: 10209252
    Abstract: A substrate comprising a microporous microstructure, an interlayer over at least a portion of the microstructure and a functional layer attached to the interlayer, the functional layer having functional sites with a density of at least 50 nanomoles/cm2.
    Type: Grant
    Filed: March 1, 2011
    Date of Patent: February 19, 2019
    Assignee: W.L. Gore & Associates, Inc.
    Inventors: Anit Dutta, Heidi Flannery, William P. Mortimer, Jr.
  • Patent number: 10195280
    Abstract: The present invention provides lipid aggregate compositions having at least two cationic lipids in combination with one or optionally more than one non-cationic lipids for the in vitro and/or in vivo delivery of biologically active molecules including nucleic acids, specifically DNA and RNA, and proteins into cells and tissues. Methods are also provided that use the compounds of the present invention to deliver biologically active molecules, into cells and tissues to facilitate the expression of target proteins therein. In some non-limiting embodiments, the subject lipid aggregate compositions can be used to deliver nucleic acid molecules to facilitate the expression of proteins involved in cellular reprogramming and genome editing applications.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: February 5, 2019
    Assignee: LIFE TECHNOLOGIES CORPORATION
    Inventors: Xavier de Mollerat du Jeu, Nektaria Andronikou
  • Patent number: 10188694
    Abstract: The present invention relates to a peptide for skin regeneration or wound healing and a use thereof. The novel peptide according to the present invention not only promotes the wound healing by increasing the production amount of collagen in dermal fibroblasts but also has an excellent whitening effect by inhibiting the production amount of melanin and tyrosinase activity of melanoma cells, and consists of peptides having a very small size to minimize side effects according to administration of external substances of very small peptides. As a result, it is expected that the novel peptide can be used as an active substance that can replace existing skin regeneration or would therapeutic agents.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: January 29, 2019
    Assignee: BIO PEP CO., LTD.
    Inventors: Dae Ho Cho, Min Chan Gil, So Mi Lee, Myun Soo Kim
  • Patent number: 10179939
    Abstract: Disclosed herein are various methods, systems, and compositions for the growth independent detection of cells such as microorganisms including bacteria. While existing cellular detection methodologies benefit from cell growth, the methods, systems, and compositions disclosed herein demonstrate embodiments that are independent of cell growth while still allowing for cell-based detection.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: January 15, 2019
    Assignee: GeneWeave Biosciences, Inc.
    Inventor: Diego Ariel Rey
  • Patent number: 10174324
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Methionine Sulfoxide Reductase A (MSRA), in particular, by targeting natural antisense polynucleotides of Methionine Sulfoxide Reductase A (MSRA). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of MSRA.
    Type: Grant
    Filed: February 10, 2015
    Date of Patent: January 8, 2019
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • Patent number: 10174373
    Abstract: The invention provides components and methods for polymerase chain reaction assays. The assays minimize both handling of material and time spent running samples. For example, a single internal positive control (SPC) polynucleotide pair can provide a means to ensure proper nucleic acid purification for both RNA and DNA test targets. Additionally, standard cycling conditions for ali diagnostic tests allow the user to run both RNA and DNA targets side-by-side.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: January 8, 2019
    Assignee: IDEXX Laboratories, Inc.
    Inventors: Christian Leutenegger, Michael John Angelichio
  • Patent number: 10174362
    Abstract: Disclosed is nucleic acid preserving compositions and methods of manufacturing and using the same. Compositions include a carrier, a chaotropic agent, a buffering agent, a chelating agent, a surfactant, an alcohol, an acid, and a mucolytic agent. Compositions as aqueous solutions can include water as a carrier. Preferred embodiments include water, guanidine thiocyanate, Tris, EDTA, SLS, SDA 3C, HCl, and N-acetyl-L-cysteine. Some embodiments include a colored dye as a visual indicator. Methods of manufacturing include combining the components into a mixture, such as an aqueous solution. Methods of use include providing a biological sample that includes nucleic acid and contacting the biological sample with the composition. Kits include the composition disposed in a portion of a biological sample collection apparatus.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: January 8, 2019
    Assignee: Spectrum Solutions L.L.C.
    Inventor: Federico Carlos Arejola Gaeta
  • Patent number: 10172930
    Abstract: Methods for purifying human Calciviruses are disclosed, including Noroviruses and Sapoviruses.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: January 8, 2019
    Assignee: TAKEDA VACCINES, INC.
    Inventors: Thomas S. Vedvick, Bryan Steadman, Charles Richardson, Thomas R. Foubert, Charles R. Petrie
  • Patent number: 10167500
    Abstract: The present invention provides nucleic acid amplification systems and methods that desirably reduce or eliminate false positive amplification signals resulting from contaminating biological material, e.g., nucleic acid, that may be present in one or more reagents used in an amplification reaction and/or that may be present in the environment in which an amplification reaction is performed. The invention offers the further advantage of requiring less stringent purification and/or sterility efforts than conventionally needed in order to ensure that enzymes and other reagents used in amplification reactions, and the environment in which an amplification reaction is performed, are free of bacterial or other nucleic acid contamination that may yield false positive results.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: January 1, 2019
    Assignee: GEN-PROBE INCORPORATED
    Inventors: Michael M. Becker, Kristin W. Livezey, Wai-Chung Lam
  • Patent number: 10167526
    Abstract: Methods of predicting whether a subject has a cervical intraepithelial neoplasia (CIN) lesion are provided. Aspects of the methods include obtaining both morphometric and biomarker data from a liquid cervical cellular sample and then using both types of data to predict whether the subject has a CIN lesion. Also provided are systems that find use in practicing the methods. The methods and systems find use in a variety of applications, including cervical cancer screening applications.
    Type: Grant
    Filed: May 19, 2015
    Date of Patent: January 1, 2019
    Assignee: IncellDx, Inc.
    Inventor: Bruce K. Patterson
  • Patent number: 10166263
    Abstract: Processes to produce microorganisms that can be incorporated into a microbial-based product that results in high viable cell yields and shelf-stable products are disclosed. These microbial-based products are useful for inhibiting pathogenic growth and as a food additive. A preferred microorganism is a lactic acid producing bacteria. In one embodiment, the process comprises inoculating either a fermentation medium with enterococcus or pediococcus bacterial cells, harvesting the enterococcus or pediococcus bacterial cells at least partially during the log phases, concentrating the bacterial cells, and preserving the bacterial cells at a concentration of at least 5×109 cfu/ml.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: January 1, 2019
    Assignee: MICROBIOS, INC.
    Inventors: Matthew Ryan Garner, Joseph F. Flint
  • Patent number: 10167520
    Abstract: The present invention includes a method for determining the identify of an organism or virus in a sample comprising the steps of: isolating DNA or RNA from the sample; combining the DNA or RNA directly or with one or more universal or target specific amplification primers, wherein the one or more primers are specific for one or more group of target microorganisms or virus; and amplifying the DNA, or the RNA following reverse transcription with a reverse transcriptase; and contacting the amplification product with one or more species-, organism- or virus-specific detectable marker.
    Type: Grant
    Filed: December 6, 2012
    Date of Patent: January 1, 2019
    Inventor: Scot E. Dowd
  • Patent number: 10160811
    Abstract: The present invention concerns dosages for treatment of human cancer patients with an anti-Epidermal Growth Factor Receptor (EGFR) antibody.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: December 25, 2018
    Assignee: Genentech, Inc.
    Inventors: Sharon A. Baughman, Steven Shak
  • Patent number: 10161010
    Abstract: The present disclosure provides methods useful for determining levels of HCMV infection in host cells and, by extension, determining levels of neutralizing antibodies present in a sample. The present disclosure encompasses the recognition that HCMV viruses that have a fluorescent moiety permit detection of viral infection (e.g., by assessing fluorescence in cells after contacting the host cell with the virus). In some embodiments, levels of HCMV infection are determined by fluorescence detection where the virus has been preincubated with a test sample (e.g., a serum sample) from a subject. In some embodiments, the subject has been administered a candidate HCMV vaccine.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: December 25, 2018
    Assignee: Variation Biotechnologies Inc.
    Inventors: David E. Anderson, Jasminka Bozic, Barthelemy Ontsouka
  • Patent number: 10160970
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of filovirus infections. In particular, the present invention relates to a method of treating filovirus infection in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one oligonucleotide comprising the sequence as set forth in SEQ ID NO:1 to SEQ ID NO:15.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: December 25, 2018
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE BORDEAUX
    Inventors: Samir Amrane, Jean-Louis Mergny, Amina Bedrat
  • Patent number: 10144956
    Abstract: This invention provides for compositions for use in real time nucleic acid detection processes. Such real time nucleic acid detection processes are carried out with energy transfer elements attached to nucleic acid primers, nucleotides, nucleic acid probes or nucleic acid binding agents. Real time nucleic acid detection allows for the qualitative or quantitative detection or determination of single-stranded or double-stranded nucleic acids of interest in a sample. Other processes are provided by this invention including processes for removing a portion of a homopolymeric sequence, e.g., poly A sequence or tail, from an analyte or library of analytes. Compositions useful in carrying out such removal processes are also described and provided.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: December 4, 2018
    Assignee: Enzo Biochem, Inc.
    Inventors: Elazar Rabbani, Jannis G. Stavrianopoulos, James J. Donegan, Jack Coleman, Dakai Liu
  • Patent number: 10144770
    Abstract: Disclosed herein are chimeric receptors comprising an extracellular domain with affinity and specific for the Fc portion of an immunoglobulin molecule (Ig) (e.g., an extracellular ligand-binding domain of F158 FCGR3A or V158 FCGR3A variant); a transmembrane domain (e.g., a transmembrane domain of CD8?); at least one co-stimulatory signaling domain (e.g., a co-stimulatory signaling domain of 4-1BB); and a cytoplasmic signaling domain comprising an immunoreceptor tyrosine-based activation motif (ITAM) (e.g., a cytoplasmic signaling domain of CD3?). Also provided herein are nucleic acids encoding such chimeric receptors and immune cells expressing the chimeric receptors. Such immune cells can be used to enhance antibody-dependent cell-mediated cytotoxicity and/or to enhance antibody-based immunotherapy, such as cancer immunotherapy.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: December 4, 2018
    Assignees: National University of Singapore, St. Jude Children's Research Hospital, Unum Therapeutics Inc.
    Inventors: Dario Campana, Ko Kudo, Charles Wilson, Kathleen McGinness
  • Patent number: 10138519
    Abstract: Described herein are methods, compositions and kits directed to amplification of nucleic acids suitable for both next generation sequencing (NGS) and a second round of sequencing as validation, such as Sanger sequencing.
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: November 27, 2018
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Heather Sanders, Hai-Rong Li, Feras Hantash, Frederic Waldman
  • Patent number: 10139418
    Abstract: The present invention relates to a process for the prediction of cell culture performance data of sample cells, a process for the isolation of said cells and a device for the prediction of cell culture performance data of sample cells.
    Type: Grant
    Filed: October 27, 2011
    Date of Patent: November 27, 2018
    Assignee: LONZA BIOLOGICS PLC
    Inventors: Dietmar Lang, Elaine B. Martin, Gary A. Montague, Christopher J. O'Malley, Tracy S. Root, Carol M. Trim, Jane F. Povey, Christopher M. Smales, Andrew J. Racher
  • Patent number: 10125173
    Abstract: The invention provides methods, compositions and kits for treating and or preventing an HIV infection. For example, HIV envelope-like polypeptides (wild-type HIV polypeptides and mimotopes) may be administered to an individual so as to induce a protective immune response to HIV. Alternatively, antibodies directed to the HIV envelope-like polypeptides may be administered to an individual to treat or prevent an HIV infection and/or one or more symptoms associated with the infection (e.g., AIDS).
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: November 13, 2018
    Assignee: Texas Biomedical Research Institute
    Inventors: Ruth M. Ruprecht, Michael Humbert
  • Patent number: 10119972
    Abstract: Provided are azido-BODIPY compounds of formula (I), cyclooctyne-based fluorogenic probes of formula (IV), and activity-based probes of formula (VI). These compounds undergo azide-alkyne cycloadditions (AAC) with to form triazolyl products. The provided compounds are useful for detection and imaging of alkyne-, or azide-containing molecules. Methods for detection and imaging biomolecules using compounds of the present disclosure are disclosed.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: November 6, 2018
    Assignee: ACADEMIA SINICA
    Inventors: Chi-Huey Wong, Jim-Min Fang, Jiun-Jie Shie
  • Patent number: 10113206
    Abstract: The present invention relates to compositions, methods, and kits for determining the presence or absence of HIV in a sample, in particular for determining HIV-1 group M, HIV-1 group O, and/or HIV-2, in particular for simultaneous determining of HIV-1 group M, HIV-1 group O, and HIV-2.
    Type: Grant
    Filed: March 21, 2014
    Date of Patent: October 30, 2018
    Assignee: Grifols Therapeutics Inc.
    Inventors: Danuta Wronska, Terri W Journigan, James D Mellott
  • Patent number: 10105456
    Abstract: The present disclosure, among other things, provides a composition of a particle including a substrate; at least a first condensation layer comprising at least a first dopant entity; and at least a second layer comprising a second dopant entity. In some embodiments, different dopant entities are included in different layers. In some embodiments, such dopant entities are or comprise detectable entities. This, in some embodiments, provided technologies achieve multi-modality particles. Among the many advantages of provided technologies include the ability to image particles by a plurality of distinct imaging modalities and/or in a plurality of contexts (e.g., pre-surgical, intraoperative and/or post-surgical environments).
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: October 23, 2018
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Stefan Harmsen, Matthew Wall, Moritz Kircher
  • Patent number: 10106849
    Abstract: The present invention provides methods for isolation of a member of a population which has one or more mutation(s) in one or more target sequence(s) in a population. The method may comprise the steps of: (a) pooling genomic DNA isolated from each member of the population in one or more dimensions; (b) amplifying the one or more target sequence(s) in the pooled genomic DNA, wherein optionally the amplification products are pooled; (c) sequencing the amplified products or obtaining the sequence reads for the amplified products, wherein, optionally, sequencing is by pair-end sequencing and further comprises merging the paired-end reads into composite read(s); (d) identifying the mutation(s) based on alignment-free sequence analysis of sequencing data, optionally by k-mer analysis and (e) identifying individual member(s) of the population comprising the one or more identified mutations in the target sequences, optionally by high-resolution DNA melting (HRM).
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: October 23, 2018
    Assignee: Vineland Research and Innovations Centre Inc.
    Inventors: Travis Wilfred Banks, Daryl John Somers
  • Patent number: 10093947
    Abstract: The invention is directed to an adeno-associated virus (AAV) vector which comprises a nucleic acid sequence encoding an antibody or antigen binding fragment that binds to nicotine or a nicotine analog. The invention also is directed to a composition comprising the AAV vector and methods of using the AAV vector to induce an immune response against nicotine in a mammal.
    Type: Grant
    Filed: February 25, 2013
    Date of Patent: October 9, 2018
    Assignee: CORNELL UNIVERSITY
    Inventors: Ronald G. Crystal, Martin J. Hicks, Jonathan B. Rosenberg, Bishnu P. De, Stephen M. Kaminsky, Robin L. Davisson
  • Patent number: 10087482
    Abstract: The present invention relates to a reaction mixture for the amplification of nucleic acids, the non-methylated cytosine bases of which have been converted to uracil bases by means of a bisulfition reaction. The invention also discloses methods for amplifying bisulfited nucleic acid and for determining the nucleic acid methylation state, and also kits based on the reaction mixture according to the invention.
    Type: Grant
    Filed: February 6, 2009
    Date of Patent: October 2, 2018
    Assignee: QIAGEN GMBH
    Inventors: Christian Korfhage, Dirk Loeffert, Ralf Peist, Nicolas Rudinger
  • Patent number: 10081831
    Abstract: A method is disclosed for calibrating a sensor element, which has an immobilized probe oligonucleotide, via which the bonding of a target nucleic acid (Z) can be detected by the sensor. In at least one embodiment, the method includes: a) bringing the sensor element into contact with a control nucleic acid (K), the melting temperature Tm(K) of which is less than the melting temperature Tm(Z) of the target nucleic acid (Z); b) hybridizing the control nucleic acid (K) to the probe oligonucleotide at a temperature T[p]<Tm(K), and detecting a positive control signal; and optionally c) modifying the stringent conditions such that T[n]>Tm(K) and detecting a negative control signal at a temperature T[n]. According to a refinement of at least one embodiment of the invention, a measuring signal of the target nucleic acid (Z) is measured at a measuring temperature T [mess], where Tm(K)<T[mess]<Tm(Z). The method is suited in particular for the calibration and quality control of microarrays.
    Type: Grant
    Filed: October 29, 2008
    Date of Patent: September 25, 2018
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Katja Friedrich, Walter Gumbrecht, Peter Paulicka, Manfred Stanzel, Renee Weber
  • Patent number: 10078080
    Abstract: Antibodies against citrullinated protein antigens (ACPA) have shown their relevance for the diagnosis and possibly pathogenesis in arthritis. Described are means and methods for determining antibodies against homocitrulline-containing proteins or carbamylated proteins/peptides (anti-CarP) for the classification of individuals suffering from, or at risk of suffering from, arthritis.
    Type: Grant
    Filed: April 4, 2017
    Date of Patent: September 18, 2018
    Assignee: ACADEMISCH ZIEKENHUIS LEIDEN H.O.D.N. LUMC
    Inventors: Leendert Adrianus Trouw, Reinaldus Everardus Maria Toes, Thomas Willem Johannes Huizinga, Petrus Antonius van Veelen, Anthony Cerami, Jing Shi
  • Patent number: 10078081
    Abstract: The present invention relates to methods for creating isotopically-labeled glycans or glycoconjugates for use in the analysis of glycans, and compositions produced from such methods. The present invention also relates to the use of isotopically labeled glycans or glycoconjugates as standards in glycan identification and/or quantification methods. In one embodiment, the method of the present invention can be used to accurately determine the levels of glycans in a sample based upon the addition of a known quantity of a standard comprising isotopically-labeled glycans to the sample prior to analysis. In one embodiment, the present invention relates to a composition for an analytical standard comprising one or more isotopically-labeled glycans or glycoconjugates.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: September 18, 2018
    Assignee: GlycoScientific LLC
    Inventors: Barry Edward Boyes, Ronald C. Orlando
  • Patent number: 10072308
    Abstract: Provided herein are methods for determining the presence or absence of an enteroviruses and parechoviruses in a biological sample. The methods involve identifying the presence or absence of a target nucleic acids from the viruses using direct amplification from a biological sample without a step of extraction of the nucleic acids, but retaining substantially the same specificity and sensitivity of methods assaying extracted nucleic acids. Also provided are methods of diagnosis using the methods provided and compositions and kits for the practice of the methods.
    Type: Grant
    Filed: April 28, 2015
    Date of Patent: September 11, 2018
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Peter Lee, Lakshmi Nair, Albert Castro, Maria Vestal, Michelle Tabb
  • Patent number: 10072063
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: March 28, 2016
    Date of Patent: September 11, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Lea Stevermann
  • Patent number: 10060913
    Abstract: Embodiments described herein may be useful in the detection of analytes. The systems and methods may allow for a relatively simple and rapid way for detecting analytes such as chemical and/or biological analytes and may be useful in numerous applications including sensing, food manufacturing, medical diagnostics, performance materials, dynamic lenses, water monitoring, environmental monitoring, detection of proteins, detection of DNA, among other applications. For example, the systems and methods described herein may be used for determining the presence of a contaminant such as bacteria (e.g., detecting pathogenic bacteria in food and water samples which helps to prevent widespread infection, illness, and even death). Advantageously, the systems and methods described herein may not have the drawbacks in current detection technologies including, for example, relatively high costs, long enrichment steps and analysis times, and/or the need for extensive user training.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: August 28, 2018
    Assignee: Massachusetts Institute of Technology
    Inventors: Timothy M. Swager, Qifan Zhang, Suchol Savagatrup
  • Patent number: 10059986
    Abstract: The present invention relates generally to methods of sequencing of polynucleotides and compounds, compositions and kits useful for sequencing of polynucleotides. The chemical compounds include nucleotide and nucleoside analogs which possess a blocking group covalently attached to the 3? hydroxyl of the sugar moiety. The blocking group may optionally be additionally covalently attached to a linker and/or detectable label. The nucleotide analogs may be ribonucleotide or deoxyribonucleotide analogs. Methods include incorporation of the reversible terminator molecules into growing polynucleotide strands by polymerase enzymes, such as in single base sequencing methodologies utilizing sequential reversible termination techniques.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: August 28, 2018
    Assignee: Centrillion Technology Holdings Corporation
    Inventors: Wei Zhou, Glenn McGall, Moti Jain, Rui Mei
  • Patent number: 10059980
    Abstract: The present invention refers to a method for immuno-histochemical staining of a formalin-fixed, paraffin-embedded tissue section comprising the steps of a) providing a solid support, b) mounting the formalin-fixed, paraffin-embedded tissue section onto the solid support, c) removing the paraffin from the formalin-fixed, paraffin-embedded tissue section, d) heating the tissue section mounted on the solid support to retrieve epitopes at 50 to 70° C. for 12 to 24 h, and e) staining the tissue section mounted on the solid support, wherein at least step e) is performed in the presence of 0.5 to 3.0 M sodium chloride. The present invention further refers to a kit for performing the method.
    Type: Grant
    Filed: January 22, 2014
    Date of Patent: August 28, 2018
    Assignee: ROCHE MOLECULAR SYSTEMS, INC.
    Inventors: Beatrix Bahle, Andrea Herold, Sabine Lohmann, Sabine Moosmann, Julian Schuster, Monika Singer
  • Patent number: 10054591
    Abstract: This invention relates generally to a microfluidic device for encapsulation, incubation, and analysis of cell surface markers or secreted molecules from a single cell.
    Type: Grant
    Filed: December 29, 2015
    Date of Patent: August 21, 2018
    Assignee: The General Hospital Corporation
    Inventors: Martin L. Yarmush, Tali Konry
  • Patent number: 10048260
    Abstract: A Positional Scanning-Synthetic Peptide Combinatorial Library (PS-SPC) searching apparatus and method using Surface Plasmon Resonance (SPR) are provided. The method includes spotting and fixing each of a plurality of peptide pools to a top of one thin metal film, inputting specific materials to the top of the thin metal film, applying a TM-mode light to a bottom of the thin metal film and exciting SPR for the thin metal film, and detecting a TM mode reflected light reflected from the thin metal film and displaying the detected light as a two-dimensional image.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: August 14, 2018
    Assignee: ELECTRONICS AND TELECOMMUNICATIONS RESEARCH INSTITUTE
    Inventors: Yo Han Choi, Moon Youn Jung, Seon Hee Park
  • Patent number: 10047349
    Abstract: A DNA polymerase, having an amino acid sequence represented by SEQ ID No. 2, or a derivative of the amino acid sequence by substitution, deletion, or addition of at least one amino acid residue. The DNA polymerase is a hybrid DNA polymerase prepared by inserting a thioredoxin binding domain (TBD) of bacteriophage T7 DNA polymerase into a DNA polymerase I (Sau) of Staphylococcus aureus. A method for preparing the DNA polymerase includes: 1) determining a corresponding position and a target substitution sequence in Sau protein for the TBD of the bacteriophage T7 DNA polymerase; 2) devising and synthesizing a primer according to a gene sequence of Sau and a sequence TBD published by GenBank; 3) cloning the Sau-TBD segment acquired in (2) to an expression vector pTrc99A to construct a recombinant vector pTrc99A-Sau-TBD; and 4) transforming Escherichia coli by the recombinant vector pTrc99A-Sau-TBD and inducing protein expression.
    Type: Grant
    Filed: September 5, 2016
    Date of Patent: August 14, 2018
    Assignee: HANGZHOU ZHONGCE BIO-SCI&TECH. CO., LTD.
    Inventors: Qi Cheng, Bing Zhai, Joseph Chow, Xianzhen Li, Guoxian Liu
  • Patent number: 10039484
    Abstract: A device for stabilizing a patient catheter includes a docking pod with a body, an inlet, an outlet, an internal fluid path between the inlet and the outlet, and a securement surface located on an underside of the docking pod. A docking pod adhesive layer located at least partially on the securement surface of the docking pod may secure the docking pod to the patient such that the securement surface and the docking pod adhesive layer form a generally planar or concave surface when secured to the patient. A valve mechanism located within the internal fluid path of the docking pod may control fluid flow through the docking pod. The device may also have a luer connector that is fluidly connected to the outlet of the docking pod and configured to be connected to the catheter.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: August 7, 2018
    Assignee: NP Medical Inc.
    Inventors: Luis Maseda, Todd Chelak, Nicholas Dennis, Ian Kimball
  • Patent number: 10041946
    Abstract: The present invention is directed to combination immunoassays, reagents and kits for simultaneous detection of HCV antigens and anti-HCV antibodies in a sample. The combination immunoassays of the present invention employ a non-ionic detergent that effectively exposes or releases the HCV core antigen from virions in a sample without interfering with the performance of other reagents such as the capture of anti-HCV antibodies by recombinant HCV antigens.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: August 7, 2018
    Assignee: Ortho-Clinical Diagnostics Inc.
    Inventors: Jian Zheng, Jianping Yang